Entera Bio Ltd.

NASDAQ:ENTX

Biotechnology

Healthcare
$3.26 +0.00%

+$0.00 today

Market cap
$567.69M
Beta
1.49
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.91High $3.22

Volume 0.49M

Average 0.16M

ENTX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Entera Bio Ltd.NASDAQ: ENTX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 47.76M shares rose 10.1% year over year, behind the +20.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 3.4% from the prior quarter. Over 3 fiscal years it compounded at +17.0% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +10.1% toward the trailing-twelve-month pace of +20.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
47.76M+3.4% QoQ
Last fiscal yearDec 2025
46.19M+22.7% YoY
LTMMar 2026
46.97M+20.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.1%——
1 year+22.7%——
3-year CAGR+17.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
46.19M USD
Year-over-year change
+22.7%
4-year CAGR
+15.3%

Weighted Avg Shares (Diluted) vs competitors

How ENTX compares with its peers on the latest reported figures

  • ENTX's LTM Mar 2026 weighted avg shares (diluted) of 46.97M shares is the 7th highest of the 10 companies compared; the peer median is 56.96M shares.
  • Its year-over-year change of +20.6% is the 5th highest of 10, against a peer median of +10.4%.
  • Over three fiscal years its annual growth of +17.0% compares with a peer median of +18.0%.
ENTX Competitors Peer median
Weighted Avg Shares (Diluted) for ENTX and competitors
Company Period LTM YoY 3-year CAGR
IRDOpus Genetics, Inc.LTM Mar 2026406.29M +1283.9%+211.4%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026312.72M +1040.7%+186.8%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 202661.23M +1.8%+14.3%
SPROSpero Therapeutics, Inc.LTM Mar 202657.24M +5.3%+16.2%
SEERSeer, Inc.LTM Mar 202656.96M -7.5%-2.7%
HURATuHURA Biosciences, Inc.LTM Mar 202650.79M +127.0%+911.7%
ENTXEntera Bio Ltd.LTM Mar 202646.97M +20.6%+17.0%
AGENAgenus Inc.LTM Mar 202633.65M +50.2%+28.3%
ANIXAnixa Biosciences, Inc.LTM Apr 202632.94M +2.7%+2.2%
MCRBSeres Therapeutics, Inc.LTM Mar 20268.99M +10.4%+18.0%
Peer median (excluding ENTX) 56.96M+10.4%+18.0%

Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue571K134K0181K42K
Cost of Revenue373K165K56K172K42K
Gross Profit198K(31K)(56K)9K0
Gross Margin34.7%-23.1%—5.0%0.0%
Research & Development6.77M5.78M4.45M4.5M6M
Selling, General & Admin5.69M7.25M4.43M5.1M5.53M
Operating Expenses12.42M13.04M8.88M9.59M11.53M
Depreciation & Amortization53K64K56K46K30K
EBITDA(12.16M)(12.87M)(8.8M)(9.48M)(11.41M)
EBITDA Margin-2130.3%-9604.5%—-5238.1%-27164.3%
Operating Income(12.22M)(13.07M)(8.94M)(9.59M)(11.53M)
Operating Margin-2139.6%-9752.2%—-5295.6%-27450.0%
Interest Income083K31K58K0
Interest Expense29K0000
Other Income / Expenses(29K)134K80K58K90K
Income Before Tax(12.25M)(12.93M)(8.86M)(9.53M)(11.44M)
Pre-Tax Margin-2144.7%-9652.2%—-5263.5%-27235.7%
Income Tax Expense(59K)137K29K14K0
Net Income(12.19M)(13.07M)(8.89M)(9.54M)(11.44M)
Net Margin-2134.3%-9754.5%—-5271.3%-27235.7%
EPS (Basic)(0.47)(0.45)(0.31)(0.25)(0.25)
EPS (Diluted)(0.47)(0.45)(0.31)(0.25)(0.25)
Weighted Avg Shares26.13M28.81M29.01M37.65M46.19M
Weighted Avg Shares (Diluted)26.13M28.81M29.01M37.65M46.19M

Entera Bio Ltd.

NASDAQ:ENTX

Intrinsic Alpha fair value

Locked

Current Price

$3.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.